# A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin

> **NCT03449251** · PHASE2 · UNKNOWN · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 170 (estimated)

## Conditions studied

- Cardiovascular Diseases
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Apelin
- **DRUG:** Relaxin
- **DRUG:** Normal saline
- **DIAGNOSTIC_TEST:** Verapamil
- **DIAGNOSTIC_TEST:** LN Monomethyl arginine

## Key facts

- **NCT ID:** NCT03449251
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-28
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03449251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03449251, "A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03449251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*